aTyr Pharma Inc. (NASDAQ:LIFE) and InflaRx N.V. (NASDAQ:IFRX) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma Inc.	N/A	0.00	34.52M	-1.33	0.00
InflaRx N.V.	N/A	0.00	N/A	-1.42	0.00

In table 1 we can see aTyr Pharma Inc. and InflaRx N.V.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the return on equity, return on assets and net margins of both companies.

	Net Margins	Return on Equity	Return on Assets
aTyr Pharma Inc.	0.00%	-78.1%	-53.6%
InflaRx N.V.	0.00%	-22.7%	-21.9%

Liquidity

The current Quick Ratio of aTyr Pharma Inc. is 5.4 while its Current Ratio is 5.4. Meanwhile, InflaRx N.V. has a Current Ratio of 18.7 while its Quick Ratio is 18.7. InflaRx N.V. is better positioned to pay off its short-term and long-term debts than aTyr Pharma Inc.

Analyst Recommendations

Recommendations and Ratings for aTyr Pharma Inc. and InflaRx N.V. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
aTyr Pharma Inc.	0	0	0	0.00
InflaRx N.V.	0	0	1	3.00

On the other hand, InflaRx N.V.’s potential upside is 49.18% and its consensus price target is $58.

Institutional and Insider Ownership

The shares of both aTyr Pharma Inc. and InflaRx N.V. are owned by institutional investors at 52.6% and 58.4% respectively. Insiders held 2.5% of aTyr Pharma Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
aTyr Pharma Inc.	-7.27%	-11.18%	-26.45%	-38.19%	-84.92%	-10.23%
InflaRx N.V.	16.4%	16.44%	25.22%	14.31%	39.39%	4.98%

For the past year aTyr Pharma Inc. has -10.23% weaker performance while InflaRx N.V. has 4.98% stronger performance.

Summary

InflaRx N.V. beats on 6 of the 7 factors aTyr Pharma Inc.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.